We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
HLK Biotech Holding Group Inc (CE) | USOTC:AMHD | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.0002 | 0.00 | 00:00:00 |
We have made presentations to interested parties to replicate our business model in other locations throughout the Caribbean. Response so far has been favorable, and presents a key growth opportunity for us in 2010.
"Also on November 5th I announced I had increased my ownership of the Company's Common shares. Since then, I have purchased an additional 100 million shares. I remain solidly committed to making the Company profitable, and increasing value to our shareholders," stated Fred Guarnieri, President and CEO.
The current Outstanding Common Shares balance is 4,309,573,155, and the Authorized 4,925,000,000. Mr Guarnieri now owns 580,600,000 shares. There have been no issuances of additional shares since August 2008.
"I'm honored to serve as your President and CEO, and would like to wish you all a safe and happy holiday season, and a very prosperous New Year for us all," concluded Mr. Guarnieri.
About Amelot Holdings, Inc. (PINKSHEETS: AMHD):
Amelot Holdings, Inc. (http://www.amelotholdings.com), a publicly traded company, is a diversified holding company that has identified Biodiesel as a multi-billion emerging Biofuel market. Amelot plans to have a significant market share in growing low cost feedstocks to supply the growing demand for biodiesel, to reduce energy dependency of fossil fuels, to help reduce the U.S. dependency on foreign oil supplies and reduce the impact of energy on our environment.
Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, our ability to obtain additional financing and access funds from our existing financing arrangements that will allow us to continue our current and future operations and whether demand for our products and services in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events.
Contact: Amelot Holdings, Inc. 1(866)-669-8373 support@amelotholdings.com http://www.amelotholdings.com
1 Year HLK Biotech (CE) Chart |
1 Month HLK Biotech (CE) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions